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Diabetes mellitus and hyperglycemia
control on the risk of colorectal
adenomatous polyps: a retrospective
cohort study
Katarzyna Budzynska1,3* , Daniel Passerman1, Denise White-Perkins1, Della A. Rees1, Jinping Xu2, Lois Lamerato1
and Susan Schooley1
Abstract
Background: Colorectal cancer (CRC) develops from colorectal adenomatous polyps. This study is to determine if
diabetes mellitus (DM), its treatment, and hemoglobin A1c (HbA1c) level are associated with increased risk of colorectal
adenomatous polyps.
Methods: This was a retrospective cohort study that included patients who had at least one colonoscopy and
were continuously enrolled in a single managed care organization during a 10-year period (2002–2012). Of these
patients (N = 11,933), 1800 were randomly selected for chart review to examine the details of colonoscopy and
pathology findings and to confirm the diagnosis of DM. Multivariable logistic regression analyses were performed
to assess the associations between DM, its treatment, HbA1c level and adenomatous polyps (our main outcome).
Results: Among the total of 11,933 patients with a mean (standard deviation) age of 56 (± 8.8) years, 2306 (19.3%) had
DM and 75 (0.6%) had CRC. Among the 1800 under chart review, 445 (24.7%) had DM, 11 (0.6%) had CRC and 537 (29.8%)
had adenomatous polyps. In bivariate analysis, patients with DM had 1.45 odds of developing adenomatous polyps
compared to those without DM. This effect was attenuated (odds ratio = 1.25, 95% CI: 0.96–1.62, p= 0.09) after adjusting
for confounders such as age, gender, race/ethnicity, and body mass index. There was no significant association between
type or duration of DM treatment or HbA1c level and adenomatous polyps.
Conclusions: Our study confirmed the known increased risk of adenomatous polyps with advancing age, male
gender, Hispanic race/ethnicity and higher body mass index. Although it suggested an association between DM
and adenomatous polyps, a statistically significant association was not observed after controlling for other
potential confounders. Further studies with a larger sample size are needed to further elucidate this relationship.
Keywords: Adenomatous polyp, Diabetes mellitus, Treatment, Colonoscopy
Background
Colorectal cancer (CRC) develops from colorectal aden-
omatous polyps. It is estimated that there will be 134,490
new cases of CRC in 2016, 49,190 of those diagnosed will
die [1, 2]. Screening colonoscopy prevents development of
CRC by removal of precursor adenomatous polyps [3].
Since it takes between 7 and 10 years for the precancerous
polyp to develop into a malignant lesion, routine screen-
ing colonoscopy has been shown to reduce the incidence
of CRC and its subsequent morbidity and mortality [4].
However, despite advances in CRC screening and treat-
ment modalities, CRC continues to be a leading cause of
mortality in the United States. This highlights the need for
more targeted interventions.
Diabetes mellitus (DM) has been found to be associated
with an increased risk of CRC [2]. Several meta-analyses
suggested that DM carries an average 30% increased risk
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of CRC [5–8]. It has been hypothesized that insulin re-
sistance and the resulting hyperinsulinemia may pro-
mote carcinogenesis by directly stimulating colonic cell
growth [9, 10]. In addition, insulin is thought to act in-
directly by binding to and activating the insulin-like
growth factor-1 receptors. Insulin-like growth factor-1
then enhances cell proliferation and inhibits apoptosis
[9–12]. Observational studies have shown an increased
CRC risk with hyperinsulinemia and elevated
insulin-like growth factor-1 levels [13]. This is concern-
ing as the number of Americans with DM has tripled
over the last 3 decades [14]. The Centers for Disease
Control and Prevention estimates that a total of 29.1
million Americans have DM and 29% of them are un-
diagnosed [14]. Additionally, it is even more concerning
as African American ethnicity is identified as a risk fac-
tor for both Diabetes and CRC [15]. African Americans,
among other minorities, have a higher prevalence and
greater burden of diabetes, and lower screening rates
for CRC [16].
Although there are strong data suggesting the association
between DM and CRC, the current literature regarding the
association between DM and adenomatous polyps, the pre-
cursor to CRC, is conflicting and has several limitations
[17–20]. Some studies only evaluated a small sample with a
short duration of exposure [21, 22] and other studies were
conducted outside the United States [6]. In addition, there
are only three studies that have evaluated the effect of gly-
cemic control on the risk of adenomatous polyps with con-
flictual findings [17, 20, 21]. The main goal of this study
was to better understand the association between DM and
the prevalence of adenomatous polyps in a large managed
care organization population. Additionally, the associations
between the type of DM treatment (oral medicine vs. insu-
lin), level of glycemic control (i.e., hemoglobin A1c
[HbA1c] level), and the prevalence of adenomatous polyps
were assessed. The study hypotheses were that: 1) patients
with DM have increased prevalence of adenomatous polyps
compared to those without DM; 2) higher HbA1c level is
associated with higher risk of adenomatous polyps.
Methods
Study population
The initial population was identified by using an admin-
istrative database of a single managed care organization
(i.e. Health Alliance Plan [HAP]) owned and operated by
the Henry Ford Health System (HFHS). HFHS is a large
metropolitan health system that spans 3 counties in
southeast Michigan, including the city of Detroit. The
study inclusion criteria were: 1) adult patients (≥
18 years); 2) continuously enrolled in HAP for 10 years,
who 3) had a colonoscopy during the second half of the
10-year period for either screening or diagnostic pur-
poses. A total of 11,933 eligible patients were identified
within 10 years (January 1, 2002 through December 31,
2012) who received care within the HFHS (Fig. 1). Of
them, 1800 patients (the sample population) were ran-
domly selected for medical record review (SPSS soft-
ware) in 2015. The medical records were then reviewed
to determine type of diabetes (type 1 vs type 2) and to
identify presence, number, and types of polyp per path-
ology report (e.g., non-adenomatous polyp, adenomatous
polyp, or CRC). The HFHS Institutional Review Board
approved this study.
Measurements of main exposure and outcome variables
The main outcome variable was presence of adenoma-
tous polyps. All of the adenomatous polyps were identi-
fied by reviewing pathology reports of the colonoscopies.
The main independent variable was having the diagnosis
of DM within study period (January 1, 2002 to Decem-
ber 31, 2012). DM was categorized further to type 1 or
type 2. In the initial total population (N = 11,933), a DM
diagnosis was based on variables collected in the admin-
istrative data using factors employed by the Healthcare
Effectiveness Data and Information Set (HEDIS) criteria
[23], a long established metric for evaluating care of DM
patients. The HEDIS criteria include the use of DM
medications as well as DM codes, a methodology that
reduces the prevalence of false positive diagnoses com-
pared to the use of diagnostic codes alone [24].
For the sample population (n = 1800) that randomly
selected for chart review, the diagnosis of DM was deter-
mined using information available from the medical rec-
ord (e.g. fasting plasma glucose ≥126 mg/dl, plasma
glucose ≥200 mg/dl at 2 h after a 75 g oral glucose load,
HbA1c ≥ 6.5%, presence of medication used to treat DM,
presence of insulin antibodies, or office notes indicating











Included if colonoscopy from 2008 to 2012 
only
Randomly selected for chart review   
1lost due to loss of specimen
1lost due to procedure cancelled due to anxiety
Fig. 1 Inclusion and exclusion of study participants. Abbreviations:
HAP, Health Alliance Plan
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Covariate assessment
Data on additional covariates were collected from ad-
ministrative databases of HFHS, including demographic
information (age, gender, and race/ethnicity), body mass
index (BMI) and HbA1c level. Age was categorized into
quintiles (≤ 50, 51–55, 56–60, and >60 years, Table 1).
BMI was calculated using height and weight measures
and categorized based on World Health Organization
criteria (normal BMI < 25, overweight 25 ≥ BMI < 30 kg/
m2, or obese BMI ≥ 30 kg/m2) [25]. We did not separate
underweight patients (BMI < 18.5 kg/m2) from normal
weight patients due to its small percentage. HbA1c was
used to represent the level of hyperglycemia control and
it was categorized as 4 levels (normal HbA1c < 5.7,
pre-DM 5.7–6.4, DM 6.5–7.9, and uncontrolled DM >
7.9) [23]. If more than one value of BMI and HgbA1c
level were available in the chart, the median of each vari-
able was used in the model. Type and length of
medication exposure for oral antidiabetic medications
and insulin were determined from filled prescriptions of
drugs from HAP database, using the number of months
of prescriptions filled prior to the date of colonoscopy,
which was categorized as none, < 2 years, and ≥ 2 years.
Statistical analyses
Sample characteristics were described using mean and
standard deviations for continuous variables and fre-
quencies (numbers and percentages) for categorical vari-
ables. Bivariate analysis was used to examine the effect
of each of the covariates on prevalence of adenomatous
polyps using chi-square test. Multivariable logistic
regression models were used to examine the associations
between the main exposure variable, DM, and the out-
come variable, adenomatous polyps, adjusted for all
other covariates. All analyses were performed using SPSS
(IBM version of SPSS Statistics 2015).
Results
A total of 11,933 patients met the study eligibility
criteria (Fig. 1). Of them, a sample of 1800 patients was
randomly selected for medical record review and this is
called “the sample population”. Two participants were
excluded from the sample population analysis: one due
to loss of the pathology specimen and one due to the
colonoscopy not performed because of patient anxiety of
the procedure and poor prep. The demographic charac-
teristics of the sample population (n = 1798) were statis-
tically similar to the total HAP population except that
the prevalence of DM diagnosis was greater in the sam-
ple population compared to total population (n = 11,933)
(Table 1). This is because more patients with DM (25%)
were identified by medical record review compared to
those identified by HEDIS criteria (19%) in the adminis-
trative database of HAP population (p < 0.0001) (Table 1).
When we used HEDIS criteria to identify patients with
DM in the sample population, we found the prevalence
of DM was similar as in the HAP population (P = 0.27,
data not shown), which confirms that our randomization
was successful. The mean age of the population (n =
1798) was 56.2 (± 9.1) years with females comprising
54% of the sample. Eighty-one percent were between
ages 50 and 64 years. Forty-nine percent were Cauca-
sian, followed by 30% African-American, 19% Hispanic,
2% Asian and 1% other/unknown. Seventy-one percent
of the population was overweight or obese, with a mean
BMI of 31.1 kg/m2 (± 7.1) (Table 1).
In the bivariate analysis (Table 2), we found signifi-
cant associations between the presence of adenoma-
tous polyps and older age (p < 0.0001), male gender
(p < 0.001), higher BMI (p = 0.004), and a diagnosis of
DM (p = 0.001). We found no significant association
between presence of adenomatous polyps and race/









Age, years, mean (SD) 56.06 (8.77) 56.20 (9.09) 0.468
≤ 50 2036 (17.1) 290 (16.1)
51~ 55 4149 (34.8) 628 (34.9)
56~ 60 3220 (27.0) 509 (28.3)
> 60 2528 (21.2) 371 (20.6)
Gender
Female 6527(54.7) 964 (53.6) 0.317
Male 5406 (45.3) 834 (46.4)
Ethnicity
Caucasian 5794 (48.6) 874 (48.6) 0.544
African American 3572 (29.9) 528 (29.4)
Hispanic 2148 (18.0) 342 (19.0)
Asian 264 (2.2) 35 (1.9)
Other/unknown 155 (1.3) 19 (1.1)
Body mass index,
kg/m2 mean (SD)
31.05 (6.86) 31.05 (7.05) 0.985
< 18.5 34 (0.3) 6 (0.3)
18.5–24.9 1660 (13.9) 255 (14.2)
25–29.9 3550 (29.7) 529 (29.4)
30–39.9 4038 (33.8) 602 (33.5)
> 40 1008 (8.4) 153 (8.5)
Missing cases 1643 (13.8) 253 (14.1)
Diabetes
No 9627 (80.7) 1353 (75.3) <.0001
Yes 2306 (19.3) 445 (24.7)
SD standard deviation
P value obtained from chi-square test
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Table 2 Characteristics among chart review sample and diabetes mellitus sample by adenomatous polyps
Variables Adenomatous polyp among chart review sample
Total
N (%)
No (N = 1261)
N (%)
Yes (N = 537)
N (%)
P value
Age, years, mean (SD) 56.20 (9.09) 55.39 (9.12) 58.09 (8.75) < 0.0001
≤ 50 290 (16.1) 233 (80.3) 57 (19.7)
51~ 55 628 (34.9) 441 (70.2) 187 (29.8)
56~ 60 509 (28.3) 347 (68.2) 162 (31.8)
> 60 371 (20.6) 233 (62.8) 138 (37.2)
Gender
Female 964 (53.6) 712 (73.9) 252 (26.1) < 0.0001
Male 834 (46.4) 549 (65.8) 285 (34.2)
Ethnicity
Caucasian 874 (48.6) 624 (71.4) 250 (28.6) 0.131
African American 528 (29.4) 380 (72.0) 148 (28.0)
Hispanic 342 (19.0) 220 (64.3) 122 (35.7)
Asian 35 (1.9) 24 (68.6) 11 (31.4)
Other/unknown 19 (1.1) 13 (68.4) 6 (31.6)
Body mass index, kg/m2, mean (SD) 31.05 (7.06) 30.70 (7.04) 31.83 (7.03) 0.004
< 18.5 6 (0.3) 6 (100.0) 0 (0.0) 0.013
18.5–24.9 255 (14.2) 196 (76.9) 59 (23.1)
25–29.9 529 (29.4) 369 (69.8) 160 (30.2)
30–39.9 855 (47.6) 405 (67.3) 197 (32.7)
> 40 153 (8.5) 98 (64.1) 55 (35.9)
Diabetes
No 1353 (75.3) 976 (72.1) 377 (27.9) 0.001
Yes 445 (24.7) 285 (64.0) 160 (36.0)
Adenomatous polyp among patient with Diabetes Mellitus (N = 445)
Age, years, mean (SD) 58.76 (9.72) 57.54 (9.34) 60.91 (10.03) 0.001
≤ 50 45 (10.1) 35 (77.8) 10 (22.2)
51~ 55 133 (29.9) 89 (66.9) 44 (33.1)
56~ 60 128 (28.8) 82 (64.1) 46 (35.9)
> 60 139 (31.2) 78 (56.1) 61 (43.9)
Gender
Female 225(50.6) 155(68.9) 70(31.1) 0.024
Male 220(49.4) 129(58.6) 91(41.4)
Ethnicity
Caucasian 169 (38.0) 107 (63.3) 62 (36.7) 0.622
African American 177 (39.8) 119 (67.2) 58 (32.8)
Hispanic 80 (18.0) 46 (57.5) 34 (42.5)
Asian 12 (2.7) 7 (58.3) 5 (41.7)
Other/unknown 7 (1.6) 5 (71.4) 2 (28.6)
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ethnicity or HbA1c level. Additionally, among patients
with DM, only age and gender were found to be asso-
ciated with adenomatous polyps. Being on insulin or
just taking oral DM medications or the length of DM
treatment were not associated with adenomatous
polyps. There were only seven people with type 1
DM in the subsample, thus no further analysis was
done in this group.
In multivariable logistic regression analysis, while the
point estimate suggested an increase in odds of aden-
omatous polyps in patients with DM when compared to
those without DM, this association was not statistically
significant (p = 0.09) after adjusting for age, gender,
race/ethnicity, and BMI (Table 3). There was no signifi-
cant association between HbA1c level and adenomatous
polyps when controlling for other factors, such as BMI.
In secondary analysis of the subsample that only in-
cluded patients with DM, neither the type of treatment
(insulin vs. oral medications) nor length of treatment
(none, < 2 years, or ≥ 2 years) was associated with aden-
omatous polyps (Table 4).
Discussion
In this retrospective cohort study, we found higher preva-
lence of colonoscopy-confirmed colorectal adenomatous
polyps with older age, male gender, and higher BMI. Al-
though having DM was significantly associated with
higher prevalence of adenomatous polyps in the bivariate
analysis, the association was attenuated in multivariable
logistic regression after controlling for age, gender, BMI,
and race/ethnicity. The odds ratio (1.25) was similar in
value to that of published data (1.30), but it did not reach
statistical significance (P = 0.09). In the subsample that in-
cluded only patients with DM, we did not find any signifi-
cant associations between HbA1c level, type or duration
of DM treatment and prevalence of adenomatous polyps.
Table 2 Characteristics among chart review sample and diabetes mellitus sample by adenomatous polyps (Continued)
Body mass index, kg/m2, mean (SD) 34.24 (7.54) 34.28 (7.47) 34.18 (7.67) 0.903
< 18.5 2 (0.4) 1 (50.0) 1 (50.0)
18.5–24.9 26 (5.8) 15 (57.7) 11 (42.3)
25–29.9 90 (20.2) 54 (60.0) 36 (40.0)
30–39.9 205 (46.1) 135 (65.9) 70 (34.1)
> 40 71 (16.0) 43 (60.6) 28 (39.4)
Hemoglobin A1c
< 5.7 15 (3.4) 10 (66.7) 5 (33.3) 0.903
5.7–6.4 126 (28.3) 78 (61.9) 48 (38.1)
6.5–7.9 214 (48.1) 140 (65.4) 74 (34.6)
≥ 8.0 71 (16.0) 47 (66.2) 24 (33.8)
Missing cases 19 (4.3)
Oral medication exposure
None 204 (45.8) 130 (63.7) 74 (36.3) 0.916
< 2 years 105 (23.6) 69 (65.7) 36 (34.3)
≥ 2 years 136 (30.6) 86 (63.2) 50 (36.8)
Insulin exposure
None 371 (83.4) 237 (63.9) 134 (36.1) 0.963
< 2 years 24 (5.4) 16 (66.7) 8 (33.3)
≥ 2 years 50 (11.20 32 (64.0) 18 (36.0)
SD standard deviation
Table 3 Multivariable logistic regression predicting adenomatous
polyps among chart review sample (N = 1798)
Odds
Ratio
95% CI P value
Lower Upper
Age (ref: ≤50 years)
51~ 55 1.97 1.35 2.86 < 0.0001
56~ 60 2.00 1.36 2.94 < 0.0001
> 60 2.59 1.74 3.86 < 0.0001
Sex (ref: Female) 1.45 1.16 1.81 < 0.0001
Ethnicity (ref: Caucasian)
African American 0.98 0.76 1.28 0.891
Hispanic 1.44 1.07 1.93 0.016
Asian 1.08 0.48 2.46 0.847
Other/unknown 1.08 0.40 2.94 0.879
Body mass index 1.02 1.00 1.04 0.022
Diabetes (ref: No) 1.25 0.97 1.62 0.091
ref reference group
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The current literature is conflicting regarding the link
between DM and colorectal adenomatous polyps. For
example, Dash et al. [19], in a nested case-control study
(917 cases and 2751 controls) among the Black Women’s
Health study, found no overall association between DM
and risk of adenomatous polyps. In contrast, Suh et al.
[6], in a retrospective study of 3505 patients in South
Korea reported that patients with DM had a higher pro-
portion of adenomatous polyps. Additionally, Eddi et al.
[17], in a case-control study (261 cases and 522 matched
controls) in the United States, found an increased risk
between DM and colorectal adenomatous polyps. The
reason for these contrasting results are not entirely clear
but could be related to differences in the study design,
population studied, and measurement and control of
potential confounders such as BMI, dietary pattern and
length of study follow-up. Further prospective cohort
studies with a longer follow-up would be needed to clar-
ify these issues.
Current literature is also conflicting regarding the link
between glucose level and risk of colorectal adenoma-
tous polyps. We did not find a significant association
between HbA1c level and the risk of adenomatous
polyps, which is consistent with that reported by mul-
tiple investigators [6, 17–19]. In contrast, Siddiqui et al.
reported, in a retrospective study with 652 male patients,
that diabetic patients with poor glycemic control had a
significantly higher prevalence of right-sided adenoma-
tous polyps [19]. This controversy may be a result of the
inherent limitation of HbA1c level to reflect the duration
or degree of hyperinsulinemia. Though it’s a measure of
glycemic control in DM patients, HbA1c level cannot be
directly translated to the length or extent of hyperinsuli-
nemia. Hyperinsulinemia appears to be a carcinogenic as
well as the insulin-like growth factors (IGF) [26, 27].
Further research is needed to investigate this
relationship.
The findings of this study confirmed that older age,
male gender, and higher BMI were associated with
the adenomatous polyps. However, no significant
Table 4 Multivariable logistic regression predicting colorectal
adenomatous polyps among diabetes mellitus patients only (N
= 445)




51~ 55 1.82 0.78 4.25 0.164
56~ 60 1.92 0.82 4.47 0.132
> 60 2.93 1.26 6.85 0.013
Sex (ref: Female) 1.46 0.95 2.24 0.084
Ethnicity (ref: Caucasian)
African American 0.84 0.52 1.36 0.479
Hispanic 1.25 0.69 2.28 0.463
Asian 1.36 0.33 5.63 0.673
Other/unknown 0.78 0.14 4.37 0.776
Body mass index 1.01 0.98 1.04 0.437
Oral medication exposure (ref: None)
< 2 years 0.81 0.47 1.39 0.440
≥ 2 years 0.91 0.56 1.49 0.716
Model 2
Age (ref: ≤50)
51~ 55 1.80 0.77 4.18 0.175
56~ 60 1.88 0.81 4.38 0.145
> 60 2.91 1.25 6.78 0.013
Sex (ref: female) 1.44 0.94 2.21 0.093
Ethnicity (ref: Caucasian)
African American 0.84 0.52 1.36 0.480
Hispanic 1.24 0.68 2.26 0.477
Asian 1.27 0.31 5.23 0.738
Other/unknown 0.75 0.13 4.20 0.741
Body mass index 1.01 0.98 1.04 0.447
Insulin exposure (ref: None)
< 2 years 1.01 0.40 2.54 0.978
≥ 2 years 1.03 0.53 1.99 0.938
Model 3
Age (ref: ≤50)
51~ 55 1.85 0.73 4.72 0.196
56~ 60 2.28 0.90 5.77 0.081
> 60 3.58 1.42 9.06 0.007
Sex (ref: female) 1.47 0.94 2.30 0.092
Ethnicity (ref: Caucasian)
African American 0.82 0.49 1.35 0.432
Hispanic 1.24 0.67 2.30 0.497
Asian 1.32 0.32 5.48 0.701
Other/unknown 0.75 0.13 4.27 0.747
Body mass index 1.01 0.98 1.04 0.483
Table 4 Multivariable logistic regression predicting colorectal
adenomatous polyps among diabetes mellitus patients only (N
= 445) (Continued)
Odds Ratio 95% CI P value
Lower Upper
Hemoglobin A1c (ref: < 5.7)
5.7–6.4 0.91 0.28 3.00 0.880
6.5–7.9 0.99 0.31 3.18 0.992
≥ 8.0 1.03 0.30 3.61 0.962
Model 1 is predicting polyps among diabetic patients on oral medication only;
model 2 is predicting polyps among diabetic patients on insulin; and model 3
is predicting polyps among diabetic patients with different levels of
Hemoglobin A1c level
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association between type or duration of DM treat-
ment and adenomatous polyp was found as some
studies suggested [17, 19]. For example, metformin
has been reported to decrease colon adenomatous
polyps while insulin therapy may increase them [28–
30]. In this study, we could not separate metformin
treatment from the use of other oral medications. In
addition, the possible protective effect of metformin or
the increased risk of insulin on colon adenomatous polyps
remains very controversial [17, 19, 21, 26, 31]. While
African-American race has been reported as a risk
factor for colorectal cancer, data is limited regarding
its association with precancerous polyps [32–37]. Our
study did not find any significant association between
African-American race and adenomatous polyps. Fur-
ther studies are needed in this area as well.
This study has a number of strengths. It was a large
retrospective cohort study of patients continually
enrolled in a closed managed care organization for
10 years, with a diverse mix of race/ethnicity. The en-
tire cohort had at least one colonoscopy and the
identification of colorectal cancer and adenomatous
polyp in the subsample were confirmed by reviewing
colonoscopy pathology reports. In addition, the diag-
nosis of DM was confirmed by chart review, as com-
pared to some of the previous studies where DM was
self-reported. This study population that had been
continuously enrolled in a closed managed care
organization facilitated the inclusion of medication
type and duration of DM treatment. Finally, only pa-
tients with a colonoscopy done in the second half of
the 10-year study period were included in the study
minimized the baseline heterogeneity of adenomatous
polyp risk in our study population.
Limitations
This study has several limitations. First, as a retrospect-
ive cohort study, the study was limited to data reliably
found in medical records. Information regarding the
possible confounders such as smoking, physical activity,
alcohol use, the length of DM and family history of CRC
were not available. Second, CRC was not analyzed since
there were too few CRC cases in this sample. Third, the
study population included only patients who had under-
gone colonoscopy, which may not be representative of
the general population. While our study population was
diverse in its mix of race/ethnicity, it cannot be general-
ized to the entire U.S. population, as this region has
overrepresentation of African American race/ethnicity
(U.S. census 13% vs and 29% our sample) and underrep-
resentation of Caucasians (U.S. census 77%, vs. 48% our
sample). Finally, the study time frame would exclude any
CRC or adenomatous polyp that may have been identi-
fied before or after the study period.
Conclusions
Our study findings provide important information and
context for future studies focusing on the association be-
tween DM and adenomatous polyp and CRC. The rela-
tionships between demographics, BMI, DM and its
treatment on the development of adenomatous polyps
and subsequently CRC are very complex. Up to now,
data are inconclusive regarding DM and adenomatous
polyp. Determining the effect of these risk factors and
their complex interactions with each other on the risk of
adenomatous polyp would be invaluable to primary care
physicians and public health policy makers. These find-
ings would have potential implications for more targeted
CRC screening in individuals with DM, thereby decreas-
ing the incidence rate and mortality from CRC. Consid-
ering the high prevalence of type 2 DM in the United
States, even a small increase in cancer risk could have
considerable consequences at a population level.
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